First-line treatment of advanced epidermal growth factor receptor mutation positive non-small cell lung cancer: A systematic review and network meta-analysis
Medlior is pleased to announce the publication of our manuscript titled, “First-line treatment of advanced epidermal growth factor receptor mutation positive non-small cell lung cancer: A systematic review and network meta-analysis.” in Future Oncology.
Recently dacomitinib and osimertinib, two tyrosine kinase inhibitors (TKIs), have received approval for the front-line treatment of patients with non-small cell lung cancer (NSCLC) with specific gene mutations (EGFR-positive). Approval, along with the inclusion of dacomitinib and osimertinib in treatment guidelines (NCCN and ESMO), have raised the question on how these therapies compare to traditional interventions in terms of efficacy, as measured by length of progression-free survival and overall survival, two indicators of disease management. However, the absence of a body of evidence from head-to-head randomized comparative studies, impedes such comparison. As such, this research study sought to compare the efficacy of dacomitinib and osimertinib to all other approved treatment interventions for NSCLC by conducting a systematic literature review and network meta-analysis.
Our study team systematically identified 15 randomized controlled trials measuring clinical efficacy of first-line TKI therapies for comparative purposes. Overall, the network meta-analysis showed that dacomitinib had a consistent trend toward improved overall survival and the highest probability of being most efficacious compared with the traditional interventions; afatinib, erlotinib, and gefitinib. Furthermore, this analysis demonstrated that dacomitinib and osimertinib resulted in improved progression free survival compared with afatinib, erlotinib and gefitinib. These results suggest that osimertinib and dacomitinib should be considered as standard first-line treatment options for patients diagnosed with advanced EGFR-positive NSCLC.
Interested in learning more?
Please read the full publication here.